文献速递关节外科

INFINITY全踝关节置换术503例早期经验与患者报告结局

Early experience and patient-reported outcomes of 503 INFINITY total ankle arthroplasties.
PubMed 文献 · Bone Joint J · 2021-01-01

这项多中心前瞻性观察研究纳入503例INFINITY固定轴承全踝关节置换术患者,随访平均16.2个月。所有功能评分在6个月、1年和2年时较基线显著改善,假体翻修率1.0%,总体并发症率8.8%,支持该假体治疗终末期踝关节炎安全有效。

要点

  • 6个月、1年、2年所有功能评分较基线显著改善。
  • 假体翻修率1.0%,总体并发症率8.8%,非翻修再手术率1.4%。
  • 患者特异性器械、关节炎类型及COFAS分型间结局无显著差异。

核心结论

  • INFINITY全踝关节置换术的早期经验与并发症结果支持其作为治疗终末期踝关节炎安全有效的假体。

研究设计与样本

  • 多中心、非发明者、前瞻性观察研究,2016年6月至2019年11月从11个专科中心招募503例INFINITY固定轴承全踝关节置换术患者。
  • 术前及术后6个月、1年、2年收集人口学、影像学及功能结局数据(AOS、MOXQ、EQ-5D-5L),采用COFAS分级对畸形进行分层。

主要发现

  • 500例患者达到6个月随访,420例达到1年随访,188例达到2年随访,平均随访16.2个月(6至36个月)。
  • 平均年龄67.8岁(23.9至88.5岁),38例(7.5%)为炎性关节炎,101例(20.0%)使用患者特异性器械,167例(33.1%)术中附加手术。
  • 所有功能结局评分在6个月、1年及2年时较基线显著改善。
  • 5例(1.0%)假体翻修,总体并发症率8.8%,非翻修再手术率1.4%,30天再入院率1.2%,一年死亡率0.74%。
  • 使用患者特异性器械、关节炎类型或COFAS分型之间结局无显著差异。

关键数值与推荐

  • 假体翻修率1.0%(5例/503例),总体并发症率8.8%,非翻修再手术率1.4%。
  • 30天再入院率1.2%,一年死亡率0.74%。
  • 7例死于无关原因,2例退出,1例失访。

临床怎么用

  • 对于终末期踝关节炎,INFINITY全踝关节置换术可显著改善功能评分且早期翻修率低。
  • 患者特异性器械、关节炎类型及COFAS分型不影响早期功能结局,可用于个体化决策参考。

局限性

  • 随访时间短,平均16.2个月,仅188例完成2年随访。
  • 为观察性研究,非发明者设计但无对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: This is a multicentre, non-inventor, prospective observational study of 503 INFINITY fixed bearing total ankle arthroplasties (TAAs). We report our early experience, complications, and radiological and functional outcomes. METHODS: Patients were recruited from 11 specialist centres between June 2016 and November 2019. Demographic, radiological, and functional outcome data (Ankle Osteoarthritis Scale, Manchester Oxford Questionnaire, and EuroQol five-dimension five-level score) were collected preoperatively, at six months, one year, and two years. The Canadian Orthopaedic Foot and Ankle Society (COFAS) grading system was used to stratify deformity. Early and late complications and reoperations were recorded as adverse events. Radiographs were assessed for lucencies, cysts, and/or subsidence. RESULTS: In all, 500 patients reached six-month follow-up, 420 reached one-year follow-up, and 188 reached two-year follow-up. The mean age was 67.8 years (23.9 to 88.5). A total of 38 patients (7.5%) presented with inflammatory arthritis. A total of 101 (20.0%) of implantations used patient-specific instrumentation; 167 patients (33.1%) underwent an additional procedure at the time of surgery. A total of seven patients died of unrelated causes, two withdrew, and one was lost to follow-up. The mean follow-up was 16.2 months (6 to 36). There was a significant improvement from baseline across all functional outcome scores at six months, one, and two years. There was no significant difference in outcomes with the use of patient-specific instrumentation, type of arthritis, or COFAS type. Five (1.0%) implants were revised. The overall complication rate was 8.8%. The non-revision reoperation rate was 1.4%. The 30-day readmission rate was 1.2% and the one-year mortality 0.74%. CONCLUSION: The early experience and complications reported in this study support the current use of the INFINITY TAA as a safe and effective implant in the treatment of end-stage ankle arthritis. Cite this article: Bone Joint J 2021;103-B(7):1270-1276.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Townshend DN, Bing AJF, Clough TM, et al. Early experience and patient-reported outcomes of 503 INFINITY total ankle arthroplasties. Bone Joint J. 2021. PMID: 34192928. doi:10.1302/0301-620X.103B7.BJJ-2020-2058.R2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。